Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Eli Lilly's Announcement Regarding Oral GLP-1 Orforglipron
Eli Lilly's Announcement Regarding Oral GLP-1 Orforglipron
Chugai to Construct a New Laboratory Building "UKX" to Strengthen Manufacturing Process Development Capabilities and Advance Environmental Initiatives
Supplementary Materials Consolidated Financial Statements for the six months ended June 30, 2025 (IFRS)
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2025)
CHUGAI PHARMA, Apr-Jun (2Q) Net Income Decreases by 13%
F. Hoffmann-La Roche Announces Half Year Results 2025
Supplementary Materials Consolidated Financial Statements for the three months ended March 31, 2025 (IFRS)
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the three months ended March 31, 2025)
CHUGAI PHARMA, Jan-Mar (1Q) Net Income Increases by 31%
F. Hoffmann-La Roche Announces First Quarter Sales 2025
(Corrections) Notice of Partial Correction to "Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan"
Eli Lilly's Announcement Regarding Oral GLP-1 Orforglipron
Corporate Governance Report of CHUGAI PHARMACEUTICAL CO., LTD.
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
Position and Policy Regarding Reduction of the Investment Unit
Notice of Distribution of Retained Earnings
Supplementary Materials for Consolidated Financial Statements for the Fiscal Year 2024.12 (IFRS)
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the fiscal year 2024)
CHUGAI PHARMA, 19% Increase in Net Income for the Last Fiscal Year, Current period performance is undisclosed., Dividend Raised by 152 yen